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Objective: The study aimed to validate a whole‐genome sequencing‐based NIPT
laboratory method and our recently developed NIPTmer aneuploidy detection soft-
ware with the potential to integrate the pipeline into prenatal clinical care in
Estonia.
Method: In total, 424 maternal blood samples were included. Analysis pipeline
involved cell‐free DNA extraction, library preparation and massively parallel
sequencing on Illumina platform. Aneuploidies were determined with NIPTmer soft-
ware, which is based on counting pre‐defined per‐chromosome sets of unique k‐
mers from sequencing raw data. SeqFF was implemented to estimate cell‐free fetal
DNA (cffDNA) fraction.
Results: NIPTmer identified correctly all samples of non‐mosaic trisomy 21 (T21,
15/15), T18 (9/9), T13 (4/4) and monosomy X (4/4) cases, with the 100% sensitivity.
However, one mosaic T18 remained undetected. Six false‐positive (FP) results were
observed (FP rate of 1.5%, 6/398), including three for T18 (specificity 99.3%) and
three for T13 (specificity 99.3%). The level of cffDNA of <4% was estimated in eight© 2019 John Wiley & Sons, Ltd.wileyonlinelibrary.com/journal/pd 1
2 ŽILINA ET AL.samples, including one sample with T13 and T18. Despite low cffDNA level, these
two samples were determined as aneuploid.
Conclusion: We believe that the developed NIPT method can successfully be used
as a universal primary screening test in combination with ultrasound scan for the first
trimester fetal examination.What is already known about this topic?
• The developed NIPT approaches are different in terms of
the genetic and bioinformatic technologies used,
computational resources required, data analysis speed,
and finally even in robustness and reliability.
What does this study add?
• Novel in‐house developed NIPTmer program counts pre‐
defined per‐chromosome sets of unique k‐mers from
sequencing data.
• NIPTmer uses less computer resources and is faster than
available NIPT‐tools.
• NIPTmer was validated for detection of fetal
aneuploidies, demonstrating its readiness for use in
prenatal testing.1 | INTRODUCTION
Aneuploidies are a major cause of perinatal morbidity and mortality. In
many countries, including Estonia, prenatal testing for fetal aneu-
ploidies relies on the first trimester combined test (FCT), including
the analysis of maternal serum biomarkers, pregnancy‐associated
plasma protein‐A (PAPP‐A) and free β‐human chorionic gonadotropin
(fβ‐hCG), and fetal nuchal translucency (NT) ultrasound, after which
women who are deemed to be at high risk are offered an invasive con-
firmatory test. The main issue associated with FCT is relatively high
false‐positive (FP) rate, about 5%, due to which ~90% of the women
eligible for the following invasive testing carry a healthy baby.1 At
the same time, invasive methods – amniocentesis and chorionic villus
sampling (CVS) result in a small but concerning risk for miscarriage,
even if the procedure is performed by an experienced specialist.2
The number of unnecessary invasive testing can be reduced signifi-
cantly if more precise primary screening methods are properly utilised.
Since 2011, non‐invasive prenatal testing (NIPT) is routinely used
for the detection of common fetal trisomies, such as trisomy 21
(T21), 18 (T18) and 13 (T13), demonstrating sensitivity and
specificity up to >99%.3,4 Several NIPT technologies have been
developed for that; including massively parallel sequencing (MPS),
chromosome‐selective or targeted sequencing and SNP (single nucle-
otide polymorphism) based approaches. In MPS‐NIPT, plasma DNA
random or “shotgun” whole‐genome sequencing is used, and a z‐
score of >3 standard deviations away from the expected read count
of a specific chromosome is considered as high‐risk indicator for
fetal trisomy of a test sample.5 On the contrary, in targeted sequenc-
ing, the plasma DNA fragments from chromosomes 13, 18 and 21
are amplified, and the enriched fragments are sequenced instead of
the entire genome, thus revealing only these three trisomies. Simi-
larly, in SNP‐based NIPT, counting of the fetal alleles and calculating
the allele ratio is used to predict the fetal trisomy for chromosomes
13, 18 or 21.6
Presently NIPT testing is growing constantly worldwide as it is
recognized as a highly precise screening test that is not more hazard-
ous for a pregnant woman than a simple blood draw procedure.
Given that NIPT offers safe and accurate selection of high‐risk preg-
nancies and enables to avoid a large number of unnecessary invasive
procedures, we aimed to validate a whole‐genome MPS‐based NIPT
laboratory method and our recently developed NIPT analysis soft-
ware (NIPTmer)7 for detecting T13, T18 and T21, and sex chromo-
some aberrations, with the potential to integrate NIPT into the
prenatal clinical care in Estonia.2 | METHODS
2.1 | Samples and study design
The study was approved by the Research Ethics Committee of the
University of Tartu (#246/T‐21) and written informed consent was
obtained from all participants. A total of 408 samples from pregnant
women were collected at Tartu University Hospital (Tartu, Estonia)
and at East‐Tallinn Central Hospital (Tallinn, Estonia) during 2015 to
2018. Singleton pregnancy with the gestational age of ≥10 weeks
was the mandatory requirement for enrolment.
The cohort included cases with both high (referred as high‐risk
pregnancies; n=259) and low (referred as general population; n=149)
risk of aneuploidy. The high‐risk factors included increased FCT‐based
trisomy risk of >1/300 for any common fetal trisomies (T21, T18
and/or T13, n=208), family history of genetic diseases (including fetal
trisomies, n=25), ultrasound abnormalities (n=15), and in rare cases
also elevated maternal age of ≥36 years or other reason (n=11). All
women from the high‐risk group underwent invasive prenatal diagnos-
tic procedure (amniocentesis or CVS followed by karyotyping, fluores-
cence in situ hybridisation (FISH) or chromosomal microarray analysis).
The type of the invasive procedure (amniocentesis or CVS) is shown in
Table S1, CVS was performed only using the long‐term culture
method.
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FCT and no detectable fetal abnormalities on ultrasound examination.
In this group of women, the general health status of a baby was deter-
mined at birth by a neonatologist.
The mean age of participants in high‐risk group was 35 years
(median 36, range 17‐47, and 25th and 75th percentiles 30 and 39,
respectively) and 29 years in general population (median 30, range
16‐41, and 25th and 75th percentiles 26 and 33, respectively). The
mean gestational age at NIPT in high‐risk group was 15 weeks
(median 15, range 11‐21, and 25th and 75th percentiles 13 and 17,
respectively) and 25 weeks in general population (median 25, range
10‐40, and 25th and 75th percentiles 20 and 33, respectively). General
characteristics of the study cohorts are summarized in Table S1.
Samples from general population were analysed by Illumina tech-
nology using massively parallel sequencing to generate preliminary ref-
erence dataset. This was initially used to analyse the data obtained
from the high‐risk group samples. The reference dataset was updated
constantly by including euploid samples from high‐risk group, which
makes further analysis more precise.
In addition, 16 cell‐free DNA samples from the Center for Human
Genetics, UZ Leuven, Belgium enriched for common trisomy cases
(T21 n=2, T18 n=3 and T13 n=3) were blindly analysed using the same
method. The results were compared with KU Leuven laboratory results.
Laboratory personnel performing NIPT were blinded to the results
of karyotyping obtained from the invasive procedures in high risk
pregnancies. As this was a validation study, no results were returned
to participants.2.2 | Sample processing and sequencing
Samples (n=424) were processed according to previously published
guidelines from KU Leuven, with minor modifications.8 Briefly, periph-
eral blood samples were collected in cell‐free DNA BCT tubes (Streck,
USA) and plasma was separated within 72h by standard dual centrifu-
gation. Cell‐free DNA was extracted from 4‐5 ml plasma using
QIAamp Circulating Nucleic Acid Kit (Qiagen, Germany). Whole‐
genome libraries were prepared usingTruSeq ChIP Library Preparation
kit (Illumina Inc., USA) as described in Bayindir et al., with 12 cycles for
the final PCR enrichment step.8 Following quantification, equal
amounts of 24 libraries were pooled and the quality of the pool was
assessed on Agilent 2200 TapeStation (Agilent Technologies, USA).
Next‐generation sequencing was performed on the NextSeq 500
instrument (Illumina Inc.) with an average coverage of 0.32× (minimum
0.08 and maximum 0.42) and producing 85 bp single‐end reads.2.3 | Fetal DNA fraction (FF) calculation
Sequencing read data was mapped with Bowtie 2.3.4.19 against
GRCh37 pre‐built Bowtie index file with pre‐set option of ‘very‐
sensitive’ and the maximum fragment length of 500 for valid paired‐
end alignments.10 Mapped data was filtered by mapping quality of
30, after which SeqFF10 with minor modifications (to optimise the filehandling in SeqFF calculation workflow) was used to calculate cell‐free
fetal DNA (cffDNA) fraction (FF) for all samples.2.4 | Detection of fetal trisomies
The plasma DNA sequencing data was analysed with our novel in‐
house developed NIPTmer software package for fetal aneuploidy
detection, which is based on counting pre‐defined per‐chromosome
sets of unique k‐mers (sequences of nucleotides) from raw sequencing
data and applying linear regression model on the counts, thus avoiding
time‐consuming read‐mapping step.7 Although whole‐genome
sequencing was performed, only the risks for T13, T18 and T21, and
sex chromosome abnormalities were blindly analysed using NIPTmer
software and compared to the results of the invasive prenatal testing,
while other autosomal aberrations were only retrospectively analysed,
if detected by invasive procedure in high‐risk pregnancies.
NIPTmer calls aneuploidies of the chromosome of interest based on
the z‐score (difference between expected and observed values, normal-
ized to the standard deviation of expected values) of the detected num-
ber of specific k‐mers compared to the expected number predicted by
linear model. The model makes prediction based on the k‐mer counts
of other autosomes and GC content of the sample and is trained on
the dataset of samples with known karyotype. NIPTmer is significantly
faster than whole‐genome mapping‐based NIPT tools, uses less com-
puter resources and does not require previous experiencewithmapping
of next‐generation sequencing reads. The time to analyse a single
sequenced sample with NIPTmer is less than 5 minutes on 32‐core
server and 20 minutes on two‐core laptop. In comparison, mapping
sequenced reads to reference genome with Bowtie2 or BWA takes
more than hour, being the time‐limiting step in mapping‐based tools.
Moreover, NIPTmer allows on‐the‐fly updating of both control and
aneuploidy datasets so the prediction accuracy gets the better themore
analyses are performed. The program is also more robust as the non‐
unique and polymorphic genome regions are discarded before the
actual analysis, in k‐mer list generation step, and thus do not introduce
additional variability in test results.3 | RESULTS
A total of 424 samples were analysed at the gestational weeks of 16‐
41, while 323 (76.2%) samples were analysed during the usual prenatal
screening window of 10 to 20 completed weeks of gestation. FF esti-
mates by SeqFF were between 3‐49% (with average of 12%), and
average FF was lower in the high‐risk group compared to the general
population (10% (range 3‐29%) vs 17% (range 5‐49%), respectively),
which may be explained by a wider gestational age range of the latter.
The average cffDNA for all 323 tests within the usual prenatal screen-
ing window was 10% (range 3‐31%).
The results of NIPT and invasive fetal testing are summarized in
Table 1. Z‐score threshold for common trisomies (T21, T18 and T13)
was set at 3.0, which allowed correct identification of all non‐mosaic
T21 (15/15), T18 (9/9) and T13 (4/4) cases (sensitivity of the test
TABLE 1 NIPT results for common aneuploidies (T21, T18 and T13), 45,X karyotype and follow‐up data of the study population (n=424).
Estonian cohort Belgium cohort
Total FP FN
High‐risk
group
General
population
Samples enriched for
aneuploid cases
Number of samples 259 149 16 424
T21
NIPT 13 0 2 15 0 0
Invasive prenatal diagnosis 13 ‐ 2 15
Neonatal follow‐up ‐ 0 ‐
T18
NIPT 8 1 3 12 3 1§
Invasive prenatal diagnosis 7 ‐ 3 10
Neonatal follow‐up ‐ 0 ‐
T13
NIPT 1 3 3 7 3 0
Invasive prenatal diagnosis 1 ‐ 3 4
Neonatal follow‐up ‐ 0 ‐
45,X
NIPT 4 0 0 4 0 0
Invasive prenatal diagnosis 4 ‐ 0 4
Neonatal follow‐up ‐ 0 ‐
FP ‐ false‐positive results; FN ‐ false‐negative results.
§Mosaic T18 case with 20% of T18 cells.
4 ŽILINA ET AL.for all common trisomies 100%; the 95% confidence intervals 78.2‐
100% for T21, 66.4‐100% for T18 and 39.8‐100% for T13). However,
one mosaic T18 remained undetected (z‐score of 2.43). FISH on cho-
rionic villi revealed the presence of T18 in ~20% of the cells, while
karyotyping using the GTG (G‐bands by trypsin using Giemsa) banding
technique of the same sample was not able to establish the percent-
age of mosaicism because of the small number of the cells analysed.
Six FP results were observed (FP rate of 1.5%, 6/398), including three
for T18 (specificity 99.3%; the 95% confidence interval 97.8‐100%)
and three for T13 (specificity 99.3%; the 95% confidence interval
97.8‐100%), while no FPs for T21 were observed (specificity 100%;
the 95% confidence interval 99.1‐100%). Two FP NIPT results for
T18 in the high‐risk group were refuted by the results of the invasive
procedure, showing the normal fetal karyotype. Four FPs were
detected among general population pregnancies (Table S1), with the
babies confirmed healthy at birth and after follow‐up of the newborns
by the neonatologist. When only the NIPT tests within the usual pre-
natal screening window of 10 to 20 completed weeks gestation were
considered, the sensitivities for all common trisomies and the specific-
ity for T21 remained 100%, the specificity for T13 increased to 100%
(as FP T13 tests were recruited beyond the screening window) and the
specificity for T18 decreased slightly to 99.1%. This means that the
positive predictive value (PPV) for the NIPT tests for 10‐20 weeks
of gestation was 100% for T13 and T21, and 75% (9/12 with three
FP T18 tests) for T18. In addition, CVS with long‐term culture method
detected one mosaic trisomy 8 (karyotype 47,XY,+8(11)46,XY(29)),but there was no evidence of it with NIPT, if sequencing data was
analysed retrospectively.
Fetal sex was determined correctly for all samples (Table S1). Five
cases with sex chromosome aneuploidies (SCA) from high‐risk group
were identified by invasive testing, of which four monosomy X (45,
X; Turner syndrome; both sensitivity and specificity of 100%) cases
were determined by NIPT (z‐scores for X chromosome between ‐8.1
to ‐16.4), however one 47,XXX karyotype remained undetected (z‐
score ‐3.3) as seen in Table S1.
For eight samples the test failed (1.9%, 8/424), as the proportion of
cffDNA in maternal plasma remained <4% (2.83‐3.99%). Slightly higher
test failure rate of 2.5% (8/323) was observed for the NIPT tests done
for pregnant women from gestational weeks of 10 to 20, representing
the timeframe for NIPT usual clinical use. Six out of these eight samples
were from the high‐risk pregnancies and twowere fromBelgiumcohort.
Despite low cffDNA fraction in two aneuploid samples from Belgium,
we were able to correctly identify T13 and T18 cases. All the rest six
cases with cffDNA fraction <4% from the high‐risk Estonian pregnan-
cies were carrying fetuses with normal karyotype.4 | DISCUSSION
The aim of the current study was to adjust previously described exper-
imental protocol from KU Leuven8 and our in‐house developed
NIPTmer analysis pipeline for detection of common fetal aneuploidies7
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health setting. To date, our validated NIPT is already implemented in
Estonian healthcare system under NIPTIFY™ name.
We analysed 424 samples including high‐ and low‐risk pregnancies
and correctly identified all non‐mosaic samples aneuploid for chromo-
somes 21 (15/15), 18 (9/9) and 13 (4/4). In the current study z‐score
cut‐off of 3 was applied for T21, T18 and T13. The relative coverage
(or z‐score) distribution among euploid and aneuploid pregnancies
depends on both technological (cell‐free DNA extraction method,
sequencing library preparation, sequencing technology, and equip-
ment used) and biological (gestational age and body mass index) fac-
tors. Thus, the actual cut‐offs for calling the elevated risk of a
trisomy should be defined in every NIPT laboratory separately.7 These
cut‐offs determine the predictive power and the proportions of FP
and false‐negative (FN) NIPT results. Setting cut‐off values stringently
minimizes the number of FP results and eventually enables to reduce
significantly the number of invasive prenatal tests, which is one of
the issues addressed by NIPT. However, one should keep in mind that
this would introduce additional FN cases that must be avoided. With
the currently established threshold value of 3, six FP results were
introduced, with the FP rate of 1.5%. Therefore, the further improve-
ment of the current approach is possible as the FP rate of <0.1% is
considered as the golden standard for NIPT studies, at least for Down
syndrome.11 However, the FP rate for T21 in the current study was
0%, as all FP tests were reported for T13 and T18. All the NIPT FP
results resulted in the birth of healthy children, as confirmed by inva-
sive prenatal testing or follow‐up of the newborns by a neonatologist.
The patients in our study did not receive any feedback on NIPT
results. However, in a clinical service, confirmatory invasive testing
should be offered to all pregnant women with high‐risk testing results
as NIPT represents a screening not a diagnostic test.12
In addition to the common trisomies in our patients’ cohort, a case
of mosaic trisomy 8 (47,XY,+8(11)/46,XY(29)) was detected by CVS
but not retrospectively by NIPT. Inability to pick up this abnormality
can be explained by <30% mosaicism and relatively low cffDNA level
(6%). The detection of chromosomal abnormalities other than T21,
T18 and T13 (sex chromosome aneuploidies, other autosomal triso-
mies, triploidy and microdeletions) has been reported and is included
in some commercial NIPT platforms with variable detection rates.13
However, this is not recommended by the American College of Obste-
tricians and Gynecologists (ACOG) and debate over clinical utility con-
tinues.14 As current MPS‐NIPT platforms are not robust enough to
reliably detect aneuploidies and clinically relevant microdeletions of
all autosomal chromosomes with high accuracy, the potentially less
expensive targeted NIPT methods might be more cost‐effective, and
could become a useful mass screening tool, as we have recently
demonstrated.15
With regard to SCAs, four cases of monosomy X were correctly
determined with current NIPT pipeline, however, a case of 47,XXX, a
syndrome with clinically mild phenotypic changes, was not detected.
As in three out of four pregnancies with Turner syndrome fetuses
the enlarged NT was observed, invasive fetal studies would likely have
been offered to these women. Moreover, screening for SCAs iscontroversial due to the varying severity of these conditions, and the
fact that NIPT is less accurate in prediction of SCA compared to com-
mon trisomies. Some studies find that FP rate is especially high for
Turner syndrome,16,17 which might be partially explained by maternal
mosaicism for monosomy X that can be a part of normal aging.18
Despite possible frequent false positive results, however, the health
problems associated with Turner syndrome are the reasons why par-
ents need this information to make decisions about their pregnancies.
For these reasons, the present clinical study included NIPT screening
for the high‐risk of Turner syndrome.
Another question concerns the possible target groups for NIPT,
which is also relevant for Estonia. It has been shown that there is no
significant difference in NIPT screening performance between high‐
risk, routine and mixed populations.19 Therefore, the question arises
what is the better way to implement NIPT into clinical practice and
who are the main target groups for this testing. In general, three
models have been proposed for incorporation of NIPT into current
screening programs.20 The first one assumes that NIPT is used as a
second‐tier screening test where women first undergo conventional
FCT and those with elevated risk are subsequently offered NIPT or
invasive testing. In this case, NIPT would be offered to ~5% of women,
thus reducing costs and FP screening results,20 but the detection rate
of the fetal trisomies would still be limited by the detection rate of the
FCT. According to the second model, women deemed to be at high
risk (e.g. ≥1:100) after conventional FCT would be offered to choose
between NIPT, invasive testing or no follow‐up, and those with the
intermediate risk (e.g. 1:101‐2,500) would be offered NIPT or no fur-
ther testing. This model is likely to offer better balance between added
cost and improved detection rate.21 However, the use of NIPT as a
secondary screening test mainly lowers the FP rate, while does not
diminish the FN rate of the initial FCT. The third model would be to
offer NIPT to all women as a primary screening test combined with
ultrasound. This would result in a higher detection rate compared with
the FCT. Recently, this last option has been chosen by countries such
as the Netherlands and Belgium where NIPT is offered to all pregnant
women since 2017. As this approach is likely to provide the best
detection rate, it is also our preferred option for NIPT implementation
in Estonia.
Various national studies evaluating NIPT performance have shown
that NIPT significantly reduces the extent of invasive testing by
between 60%22 and 75%.23 Although, there is still controversy on
the magnitude of the fetal loss rate caused by invasive testing, the
reduction of invasive procedures is certainly perceived as better care
by both health care providers and pregnant women.22 In addition,
offering NIPT to high‐risk pregnant women before invasive prenatal
testing helped to drop the number of women refusing further test-
ing,24 leading to increased detection of fetal chromosomal
aberrations.25
In our study, 15 women from high‐risk group of patients demon-
strating fetal abnormalities in the ultrasound examination with or with-
out increased combined risk for common trisomieswere enrolled (Table
S1). In four of these pregnancies chromosomal aberrations were found
using NIPT (two cases of T18, a single case of T13 and a monosomy
6 ŽILINA ET AL.X), which were concordant with the findings from the invasive testing.
However, it is very important to emphasize that pregnancies with the
identified fetal malformations are certainly not the patients for whom
the NIPT should be offered, as the invasive testing is the primary choice
for them. In the present study, NIPT analysis was conducted in parallel
to the invasive prenatal testing in order to get the valuable feedback
about the accuracy of the developed NIPTmer method.
The reference group (general population, low risk for fetal triso-
mies) for NIPTmer analysis in our study consisted of patients with
wide range of gestational ages (10‐40 weeks). No limitations on gesta-
tional age were applied to the reference group in order to validate
NIPTmer and SeqFF programs in samples with low as well as with high
FF levels. The high‐risk group, however, comprised of patients with
gestational age suitable for NIPT analysis prior to invasive testing.
The gestational age is one of the most important variables that affects
the size of FF, which in turn can lead to testing failure, and possible FN
results, if the cffDNA percentage is low in early stages of pregnancy.
The test failure rate of 1.9% was observed in the present study for
all NIPT tests, as the proportion of cffDNA in maternal plasma
remained <4% in 8 samples out of 424, which is a widely accepted
minimum that allows reliable detection of common trisomies.5,12,14 In
these cases, the recommendation is to repeat the testing until the
cut‐off of 4% of cffDNA is achieved.
We also demonstrated that by limiting the analysis with the sam-
ples representing the usual prenatal screening window of 10‐20 com-
pleted weeks of gestation, that had lower FF, did not influence the
accuracy of testing in terms of sensitivity and specificity for the
analysed chromosomal conditions. However, we saw slightly increased
test failure rate of 2.5% for the NIPT tests from 10‐20 weeks of ges-
tation, when compared to 1.9% if all tests were included, indicating
that the lower fraction of cffDNA at earlier stages of pregnancy may
increase failure rates.
In conclusion, we validated next‐generation sequencing‐based
NIPT method and original NIPTmer software in Estonian population
setting. Our NIPT methodology proved to perform efficiently in
detecting common fetal aneuploidies T21, T18, T13 and monosomy
X with 100% sensitivity, and 99.3‐100% specificity. We believe that
the developed NIPT method can successfully be used as a universal
primary screening test in combination with ultrasound scan for the
first trimester fetal examination.ACKNOWLEDGEMENTS
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